Terms: = Sarcomas AND XPA, XPAC, 7507, ENSG00000136936, XP1, P23025 AND Treatment
3 results:
1. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract] [Full Text] [Related]
2. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
Aune GJ; Takagi K; Sordet O; Guirouilh-Barbat J; Antony S; Bohr VA; Pommier Y
Clin Cancer Res; 2008 Oct; 14(20):6449-55. PubMed ID: 18927284
[TBL] [Abstract] [Full Text] [Related]
3. Knockdown of XAB2 enhances all-trans retinoic acid-induced cellular differentiation in all-trans retinoic acid-sensitive and -resistant cancer cells.
Ohnuma-Ishikawa K; Morio T; Yamada T; Sugawara Y; Ono M; Nagasawa M; Yasuda A; Morimoto C; Ohnuma K; Dang NH; Hosoi H; Verdin E; Mizutani S
Cancer Res; 2007 Feb; 67(3):1019-29. PubMed ID: 17283134
[TBL] [Abstract] [Full Text] [Related]
